Skip to main content
main-content

GLP-1 receptor agonists


Browse the latest news, expert commentary, and educational content on the GLP-1 receptor agonist medication class.


Highlights

23-03-2021 | Semaglutide | Commentary | Article

STEP 4: Long-term semaglutide treatment combats weight regain

Domenica Rubino discusses the chronicity of obesity, and how STEP 4 demonstrates the need for long-term semaglutide treatment to avoid weight regain (5:59).

23-03-2021 | Semaglutide | News

STEP 4: Long-term treatment needed for full semaglutide benefit

People with obesity continue to lose weight if they remain on semaglutide 2.4 mg after an initial 20 weeks of treatment, but gradually regain it if they switch to placebo, show the STEP 4 findings.

08-03-2021 | Immunotherapy | News

Anti-IL-21, liraglutide combination may warrant further investigation for early type 1 diabetes

Phase 2 study results suggest that add-on treatment with an anti-IL-21 antibody plus liraglutide could preserve endogenous insulin secretion in people with recent-onset type 1 diabetes.

More on GLP-1 receptor agonists

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits